Molson Coors Drives Growth on Premiumization and Other Strategies

Molson Coors’ Horizon 2030 strategy emphasizes premiumization and portfolio expansion, with momentum in above-premium brands (e.g., Peroni, Blue Moon, Coors Banquet) while value brands are supported via targeted innovation. The company is executing a three-year $450 million cost savings program to offset inflation and fund investments, though near-term headwinds include sluggish Americas performance and a soft beer industry. Valuation remains a key point of focus: TAP trades at a 7.91x forward P/E versus the industry’s 14.99x, while the Zacks consensus EPS for 2026 declines 11.4% and 2027 is expected to grow 4.2%.

Analysis

TAP’s setup is less about a re-rating story and more about whether management can turn mix improvement into durable per-share compounding. In the next 1-3 months, the stock likely trades on quarterly proof that pricing is offsetting volume erosion; absent that, the low multiple can stay low because the market will treat margin support as temporary. The relative winners are the premium beer shelf and adjacent RTD/cocktail formats, while the pressure stays on sub-premium share givers and regional craft players that lack the scale to fund promotions.

The second-order risk is that cost savings become a substitute for demand growth. A three-year savings plan can protect EBITDA, but it also raises the bar for investor patience: if Americas weakness persists, the market will eventually discount those savings as maintenance capex in disguise rather than a structural margin expansion. Over 6-18 months, the key question is whether beyond-beer acquisitions contribute enough incremental gross margin to offset the secular drag from beer category softness; if not, the multiple gap to staples peers is justified.

Contrarian view: the consensus may be underestimating how much bad news is already embedded. At sub-8x forward earnings, TAP does not need strong volume growth to outperform; it only needs stabilization in depletions and no further estimate cuts. The cleanest falsifier is another round of 2026 EPS downgrades or evidence that premium mix is plateauing, which would remove the main support for both margin and valuation.

Key Decisions for Investors

• Watchlist, not a chase: wait for the next earnings print to confirm flat-to-up premium-brand depletions before adding TAP. If volumes keep deteriorating, the low multiple is likely a value trap rather than a rerating candidate.
• Relative-value trade: long TAP / short SAM or BUD on a 3-6 month horizon. TAP has the cleaner cost-out story and less valuation risk; thesis breaks if peers show stronger premium share gains or TAP’s 2026 EPS is cut again.
• If expressing a bullish view, use call spreads rather than common stock: TAP Jan-2027 calls funded by selling higher-strike calls. That captures rerating optionality if margin recovery is real, while capping downside if the beer category stays soft.
• Keep MED, NOMD, and UNFI on a separate screen only as defensive staples sentiment proxies; there is no strong fundamental read-through from this item, so do not force a basket trade.